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Abstract 
Lisinopril an antihypertensive drug was subjected to stress degradation, since the drug is 
photosensitive undergo hydrolysis and oxidized in presence of oxygen. Hence the objective of the study was to 
stress degrade Lisinopril & to find out the pathway for stress degradation of Lisinopril. Stress testing methods 
are screening methods to be used to understand the degradation chemistry of a drug. Lisinopril was subjected 
to stress degradation under different conditions recommended by International Conference on Harmonization 
(ICH). The chromatographic separation of Lisinopril & its degradation products was done on C18 column & 
mobile phase was mixture of Methanol & Water in ratio 80:20, pH 3.5 adjusted with orthophosphoric acid at a 
flow rate of 1ml/min using UV detector with λmax 220nm. The quantification & characterizations of degraded 
products were carried out by UV, IR spectroscopy & HPLC. The mechanism of degradation was confirmed by 
GC-MS fragmentation pattern. 
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1. Introduction 
Lisinopril, (LIS), (2S)-1-[(2S)-6-amino-
2[[(1S)-1-carboxy-3-phenylpropyl] amino]-
hexanoyl]-pirrole-2-carboxylic acid1 used in the 
treatment of essential hypertension, symptomatic & 
asymptomatic left ventricular systolic dysfunction, 
post-myocardial infarction, renal failure & diabetic 
nephropathy. The analysis of Lisinopril was reported 
by RP-HPLC method in bulk & tablet dosage form. A 
novel RP-HPLC method was developed for 
simultaneous estimation of Lisinopril in combination 
for bulk & tablet dosage form2. The pharmaceutical 
products are prone to undergo degradation in various 
physical & chemical conditions & yield impurities 
which adversely affect the performance of drug 
substance. Hence, it has been mandated by regulatory 
agencies of various countries to submit the stability 
indicating data of the drug substance & the drug 
product before the approval for commercialization of 
products. Hence it is necessary to develop stability 
indicating method for analysis of drug substance & 
their impurities. There is no reported stability 
indicating analytical method for analysis of Lisinopril 
& its degradation products in bulk. The present work 
aimed at the stress degradation study of Lisinopril in 
bulk & establishment of structures of degraded 
product by sophisticated instrumental methods like 
UV, IR, RP-HPLC and GC-MS3.  
 
Structure of Lisinopril4 
2. Materials and Methods 
2.1 Instrumentation: The UV spectrophotometer 
was used of model SHIMADZU UV 1650-PC. IR 
spectrophotometer was used of model SHIMADZU 
8400S. The high pressure liquid chromatographic 
(HPLC) system used was of model SHIMADZU 
8400S Prominence SPD-20Am Gradient System 
equipped with Hamilton injector & UV visible 
detector. A Phenomex HPLC column C18 reverse 
phase, 5µm, (50×4.6mm) was used. The GC- MS 
instrument of model- Accu TOF GCV, model no-
7890 with FID detector, head space injector & 
combipal autosamlper & mass range 10-2000amu, 
mass resolution 6000 was used for analysis. 
2.2 Materials: Lisinopril bulk was obtained as a gift 
sample from Mylan Laboratories, Aurangabad, India. 
Methanol & water HPLC grade obtained from Fischer 
Scientific, Mumbai. Orthophosphoric acid (Sd fine 
chemicals).  
2.3 Methods 
2.3.1 Selection of Wavelength: The wavelength of 
maximum absorption for Lisinopril was recorded by 
UV spectrophotometer (figure 1). 
Fig no.1 UV spectrum for Lisinopril 
                                                 
2.3.2 Preparation of mobile phase:  The mobile 
phase was prepared in the ratio 80:20 v/v (methanol: 
water). The pH was adjusted to 3.5 with 
orthophosphoric acid, filtered & degassed   with 
sonication for 10 mins. 
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2.3.3. Preparation of Standard solution: UV 
spectrum was recorded using spectroscopic grade 
water as solvent5. For HPLC analysis, a standard 
stock solution was prepared by dissolving 100 mg of 
Lisinopril in 100 ml of mobile phase. 1 ml of above 
solution was diluted to 100 ml with mobile phase to 
obtain a concentration of 10µg/ml & further it was 
diluted to 100ml with mobile phase to obtain a 
concentration of 1 µg/ml. Lisinopril chromatogram is 
given in fig 4.  
2.3.4. Preparation of calibration curve: For 
calibration by UV spectrophotometer, six standards 
were prepared having concentrations in the range of 
3-18µg/ml using water as a solvent. (Table 1 & fig 2). 
For HPLC analysis, six standards were used having 
concentrations in the range 0.6-1.6 µg/ml diluting 
with mobile phase. (Table 2 & Fig 5) 
2.3.5. Recording IR spectra:  The IR spectrum of 
Lisinopril was recorded using kBr pellet technique.6 
(fig no.3) 
2.3.6. System suitability Tests: System suitability 
was verified by injecting working standard of 1µg/ml. 
Various parameters such as HETP, number of 
theoretical plates, tailing factor & asymmetry were 
recorded. (Table 3) 
2.4. Validation parameters as per ICH guidelines: 
The UV & HPLC methods were validated in terms of 
precision, LOD, LOQ, linearity, range, ruggedness & 
robustness7. 
2.4.1. Precision: The precision of proposed methods 
were evaluated by carrying out six independent test 
values. Intraday & Interday precision were carried 
out. 
2.4.2. Limit of Detection & Limit of Quantitation:  
The limit of detection (LOD) & the limit of 
quantitation (LOQ) for Lisinopril by UV & HPLC 
were reported from standard deviation of the response 
& the slope. 
                        LOD= σ/S × 3.3 
                          LOQ= σ/S × 10 
 2.4.3. Robustness: The robustness of the method 
was determined as measure of the analytical method 
capability to be unaffected by deliberate small change 
in method parameters. The changes made such as use 
of single beam instrument for double beam, variation 
in flow rate by  0.2 ml/min, variation in wavelength 
by  2nm. At these changed conditions the standard 
solutions were analyzed. S.D & % R.S.D were 
calculated. 
2.4.4. Ruggedness:  The ruggedness of the method 
was checked by changing analyst & expressed as S.D 
& % RSD.  
2.4.5. Force degradation study: To check the 
stability, the drug was forced degraded under 
acid/base hydrolytic, oxidative & Photolytic stress 
conditions as per ICH recommendation8.  
The drug was subjected to acid hydrolysis by 
using 0.1 N hydrochloric acid for 6hrs at 400C; base 
hydrolysis by using 0.1N sodium hydroxide solution 
for 6 hrs at 400C; oxidation by using 6% solution of 
hydrogen peroxide for 6 hrs & photolytic stress using 
sunlight for 72hrs9. 
2.4.6. Characterization of degraded product by 
GC-MS study: The fragmentation pattern was used 
for mechanism of degradation by various degraded 
process. Fig no.10, 12, 14, 16 respectively. 
 
3. Results and Discussion 
3.1 Method development 
3.1.1. UV Method development: Water was used as 
a solvent for recording UV spectrum. The λ max 
selected was 205 nm. The UV method was developed 
& validated as ICH guidelines. Table no. 1 
Table No.1 Summary for UV Method validation of 
Lisinopril 
Parameter Observation 
Linearity 3-30µg/ml 
Slope 0.0291 
Intercept 0.0259 
Correlation Coefficient 0.988 
Precision S.D 0.0084 
% RSD 1.92 
Intraday Precision S.D 0.0074 
% RSD 1.60 
Interday Precision S.D 0.0072 
%R.S.D 1.58 
Ruggedness S.D 0.0049 
% RSD 1.20 
Robustness S.D 0.0076 
%RSD 1.64 
LOD 0.95 
LOQ 2.88 
3.1.2. HPLC Method development: Several mobile 
phase compositions were tried to resolve the peaks of 
Lisinopril & its degradation products. The mobile 
phase containing methanol- water 80:20 (v/v) was 
optimized for analysis since it resolved the peaks of 
Lisinopril (RT = 2.28 ± 0.02) with resolution factor of 
5.6. The pH was adjusted to 3.5 with orthophosphoric 
acid. The system suitability parameter was stated in 
Table no.3 Quantification was achieved with UV 
detection at 205nm on the basis of peak area. A 
typical chromatogram was obtained. The HPLC 
method developed & validated as per ICH guidelines 
for quantitation of force degraded products10. Table 
no. 2 
Table No.2 Summary for method validation of 
Lisinopril by HLPC 
Parameters Observations 
Linearity 0.6- 1.6 μg/ml 
Slope 270.97 
Intercept 10.79 
Correlation coefficient 0.995 
Precision 
S.D 1.250 
%RSD 0.45 
Intraday Precision 
S.D 0.463 
%RSD 0.16 
Interday Precision 
S.D 0.652 
%RSD 0.23 
Ruggedness 
S.D 0.430 
%RSD 0.16 
Robustness 
S.D 0.726 
%RSD 0.30 
LOD 0.015 
LOQ 0.046 
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Table No.3 System suitability parameters for Lisinopril 
Retention time Tailing factor Asymmetry Theoretical plate Resolution 
2.28 1.23 1.89 4426.65 5.68 
 
Table No.4 Comparative data for % degradation by UV & HPLC 
Compounds Hydrolysis Acid Hydrolytic 
Base 
Hydrolytic 
Base 
Photolytic 
% Degradation by UV 67.83% 69.95% 73.27% 59.83% 
% Degradation by HPLC 92.81% 93.36% 94.50% 89.85% 
 
3.2 Force Degradation 
 Forced degradation studies were carried out 
for Lisinopril in acid hydrolysis, alkaline hydrolysis, 
oxidation & photolytic stress11. The peaks of 
degradation components were well resolved & 
appeared at 2.3, 3.2, 2.8 & 2.9 respectively.fig no.6-9.   
The % degradation of Lisinopril was 
quantified by UV & HPLC methods the comparative 
data is presented in table no.4. Since HPLC is more 
specific & selective method the % degraded amount 
is more for HLPC as compared to UV method. 
3.3. Mechanism of degradation 
The structure of degraded products was 
confirmed by GC-MS study. The fragmentation patter 
was correlated with the structure of degraded 
products12. 
For acid hydrolysis degraded product formed 
Benzenebutanoic acid & the pathway of degradation 
was stated in fig no.11 
For base hydrolysis degraded product 
formed Benzene fragment & the pathway of 
degradation was stated in fig no.13 
For oxidation degraded product formed P-Toluene & 
the pathway of degradation was stated in fig no.15 
For photolysis degraded product formed & the 
pathway of degradation was stated in fig no.16. 
 
Fig no.2 Graph for Linearity of Lisinopril 
 
 
 
Fig no.3 IR spectrum for Lisinopril 
 
 
            
Fig no.4 HPLC chromatogram for Lisinopril 
 
 
Fig no.5 Graph for linearity for Lisinopril by 
HPLC 
 
 
Fig no.6 HPLC chromatogram for acid hydrolytic 
degraded   product 
 
 
Fig no.7 HPLC chromatogram for base hydrolytic 
degraded product 
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Fig no.8 HPLC chromatogram of oxidation 
degraded product 
 
 
 
Fig no.9 HPLC chromatogram of photolytic 
degraded product 
 
 
 
Fig no.10 GC-MS spectra of degradation of 
Lisinopril by acid hydrolysis 
 
 
 
 
 
 
 
 
 
Fig no.11 Fragmentation pattern for acid 
hydrolytic degraded product 
 
 
 
Fig no.12 GC-MS spectra of base hydrolytic 
degraded product 
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Fig no.13 Fragmentation pattern for base 
hydrolytic degraded product 
 
 
Fig no.14 GC-MS spectra oxidation degraded 
product 
 
 
Fig no.15 Fragmentation pattern for oxidation 
degraded product 
 
 
 
 
 
 
 
 
 
 
p- Toluene 
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Fig no.16 GC-MS spectra photolytic degraded 
product 
 
 
Fig no.17 Fragmentation pattern for photolytic 
degradation product 
 
4. Conclusion 
The forced degradation of Lisinopril was 
carried out as per ICH guidelines. The structures of 
degraded products were established by UV, IR & 
HPLC. A stability indicating validated UV & HPLC 
methods were developed for quantification of 
degraded products of Lisinopril. The mechanism of 
degradation was proved by GC-MS studies. 
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